---
title: "Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286246864.md"
description: "Shanghai Henlius Biotech, Inc. has received Australian approval for a phase 1 clinical trial of HLX48, a bispecific antibody-drug conjugate targeting EGFR and c-MET for advanced solid tumors. This therapy aims to combine targeted drug delivery with immune mechanisms to inhibit tumor growth. If successful, it would be the first bispecific ADC against both targets. The company warns of the risks in development and commercialization. Analysts rate the stock as a Buy with a price target of HK$99.78, and the current market cap is HK$39.13B."
datetime: "2026-05-13T10:14:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286246864.md)
  - [en](https://longbridge.com/en/news/286246864.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286246864.md)
---

# Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.

Shanghai Henlius Biotech has obtained Australian approval to begin a phase 1 clinical trial for HLX48, a bispecific antibody-drug conjugate targeting EGFR and c-MET for advanced or metastatic solid tumors. The therapy is designed to combine targeted cytotoxic payload delivery with immune-mediated mechanisms to inhibit tumor growth while aiming for a favorable safety profile.

Preclinical data suggest HLX48 offers promising anti-tumor efficacy, and it would be the first bispecific ADC against both EGFR and c-MET if successfully commercialized globally. The company, however, cautions investors that successful development and commercialization are not guaranteed, underscoring both the opportunity and clinical risk inherent in this early-stage asset.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

**More about Shanghai Henlius Biotech, Inc. Class H**

Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company specializing in the independent development of innovative biologic drugs, including antibody-based therapies. Listed in Hong Kong, the company focuses on oncology and other serious diseases, targeting global markets through both in-house R&D and international clinical development.

**Average Trading Volume:** 934,733

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$39.13B

### Related Stocks

- [02696.HK](https://longbridge.com/en/quote/02696.HK.md)

## Related News & Research

- [Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N](https://longbridge.com/en/news/285838804.md)
- [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md)
- [KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy](https://longbridge.com/en/news/287059695.md)
- [Hansoh Pharma Wins NMPA Breakthrough Status for Fourth-Gen Lung Cancer Drug](https://longbridge.com/en/news/287208778.md)
- [Beijing Biostar clarifies HK$ 4 subscription price, corrects agreement date to May 6](https://longbridge.com/en/news/287220187.md)